Press release: Report from Annual General Meeting in Nexam

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Press release: Report from Annual General Meeting in Nexam Chemical.

Today, on May 12, 2015, Nexam Chemical Holding AB (publ) held its Annual General Meeting. At the AGM, 9 656 001 shares were represented, approximately 18,7 % of all shares. A summary of the resolutions follows. All resolutions were passed with the required majority. Adoption and appropriation of profits The AGM resolved to adopt the presented Income Statement and Balance Sheet, and the Consolidated Income Statement and Consolidated Balance Sheet. The Meeting also resolved to appropriate the Company’s profit or loss in accordance with the Board of Directors’ proposal in the Annual Accounts. Additionally, the Meeting resolved that no dividend is paid for the financial year 2014. Discharge from liability The AGM resolved to discharge the Board members and Chief Executive Officer from liability. Remuneration The AGM resolved that the remuneration of the Board of Directors shall be in total SEK 450,000 of which SEK 150,000 is remuneration to the Chairman and SEK 100,000 is remuneration to every other Board member who is not employed by the company. The Meeting also resolved that, as in the previous year, auditors’ fees are payable in accordance with approved account, on the customary debiting terms. The Board Lennart Holm, Cecilia Jinert Johansson and Daniel Röme were re-elected Board members. Per-Ewe Wendel was new elected Board member. Lennart Holm was re -elected as Chairman of the Board. Auditor The AGM resolved to elect Mazars SET Revisionsbyrå AB as the Company’s new auditor until the next AGM. Instruction for the Nomination Committee The AGM resolved that the work for the Nomination Committee for the AGM 2016 should be conducted in accordance with the proposal, see item 12 in the notice to the AGM published on 13 April 2015. Basically, the guidelines imply that the nomination committee should consist of one member of each of the three largest shareholders based on the shareholder statistics from Euroclear Sweden AB as of June 30 2015. The Chair of the Nomination Committee shall be the member appointed by the largest shareholder in terms of the number of votes, unless the members agree differently. Information on the members of the Nomination Committee and the shareholders they represent should be published in press releases no later than six months prior to the following AGM. Remuneration policy The AGM resolved on remuneration policy for senior executives in accordance with the proposal, see item 13 in the notice to the AGM published on 13 April 2015. The remuneration for the CEO and other senior executives may be fixed salary, pension, other benefits and share-based incentive programs. The guidelines means i.e. that the CEO and other senior executives will be offered a fixed salary that is on market terms. The remuneration of the CEO and other senior executives is based on factors such as work tasks, expertise, experience, position and performance. The guidelines shall be applied to new agreements, or changes in existing agreements reached with senior executives after the guidelines have been adopted, and until new or revised guidelines are determined. Resolution on issuance of warrants and approval of transfer of warrants The AGM resolved for an incentive program in accordance with the proposal, see item 14 in the notice to the AGM published on 13 April 2015. The incentive program covers the issuance of a maximum of 646,000 warrants offered to senior executives and key persons in the Nexam Chemical Group at market value. Each warrant entitles the holder to subscribe for one new share in Nexam Chemical against cash payment at a subscription price corresponding to 150 percent of the volume weighted average last closing price for Nexam Chemical’s share on Nasdaq First North during the 13 May – 26 May 2015. The warrant may be exercised during the period from 13 September - 17 September 2018. It was noted that the resolution was taken unanimously by the AGM. Authorization for the Board of Directors to decide on the new issue of shares The Meeting resolved to authorize the Board of Directors to decide on a new issue of shares, with or without waiving the preferential rights of shareholders on one or more occasions in the period until the next Annual General Meeting. Issues may be made with or without the provisions regarding contribution in kind, set-off or other conditions. The number of shares that may be issued may not exceed a total of 12,944,000 shares. The dilution may, upon full exercise of the authorization, amount to a maximum of approximately twenty (20) per cent. The purpose of the authorization is to enable to raise working capital, to enable to execute and finance acquisitions and to enable new issues to industrial partners within the framework of partnerships and alliances. To the extent the authorization is used for new issues with deviation from the shareholders’ preferential rights, the issue price shall be on market terms. The resolution was made in accordance with the proposal, see item 15 in the notice to the AGM published 13 April 2015. It was noted that the resolution was taken unanimously by the AGM. Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Lennart Holm, Chairman of the Board, +46-706 30 85 62, lennart.holm@nexamchemical.com Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com About Nexam Chemical Nexam Chemical is a Swedish company with a world-leading technology within the area heat-activated crosslinking of plastics and polymers. The company develops, manufactures and markets unique heat-activated crosslinkers to the plastics ­market.  A company description and more information about the business will be found on www.nexamchemical.com. The company’s Certified Adviser is Remium Nordic AB.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elong Kicks Off Central Asia Strategy with Almaty Launch

Updated Category News Views 70

Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...

Continue Reading
AptarGroup Faces Investigation: Shareholder Stakes High

Updated Category News Views 89

AptarGroup Directors Under Investigation Every seasoned investor knows the market isn’t just sunshine and rainbows. Lately, the storm clouds have gathered over AptarGroup, Inc. (NYSE: ATR). Out of nowhere comes Purcell & Lefkowitz LLP, announcing a shareholder investigation that sends shivers down the spines of those who've put their money on this packaging...

Continue Reading
24X Partners with Standard Chartered for Crypto Leap

Updated Category News Views 86

24X Steps Up the Game with Crypto Addition You gotta give it to 24X—they're not just twiddling their thumbs in the background. These folks in Bermuda have snagged another feather in their cap by expanding their partnership with heavyweight Standard Chartered, bringing Bitcoin and Ethereum into the mix. We're talking big moves here as 24X becomes the first to offer...

Continue Reading
Cloud Software Group's $2B Debt Offer Wraps Up

Updated Category News Views 191

Sizing Up Cloud Software Group’s Recent Maneuver Whoever thought navigating debt was a dull spectacle hasn’t kept up with Cloud Software Group's recent financial theatrics. With a $2 billion cap on the table, their cash tender offer for 9.00% Senior Secured Second Lien Notes due 2029 didn’t just happen; it paraded onto the financial stage and left a noteworthy...

Continue Reading
Sino Biological Boosts AI Protein Discovery Efficiency

Updated Category News Views 37

Dissecting the Bridge Between AI and Biology In the cutthroat world of biotech, every second counts. Sino Biological is taking a good hard look at bridging AI and practical applications with their shiny new 4RISE™ solution. The stakes couldn't be higher—turning computer-generated protein ideas into lab-tested realities is no small feat. And believe me, researchers...

Continue Reading
VT Markets Unites Trading and Drama in New Finale

Updated Category News Views 76

Trading Meets Reality Show Drama Just when you thought you'd seen it all in the trading world, VT Markets rolls out a new spectacle. They're launching the Gold Cup 2026, an unscripted reality show stuffed with enough drama and tension to keep any trader on the edge of their seat. This isn't your run-of-the-mill trading competition; this is an injection of pure adrenaline...

Continue Reading
Poland's Economic Boom: A Case for Freedom and Growth

Updated Category News Views 60

Poland's Remarkable Journey to Economic Power Freedom, they say, fuels progress—and Poland stands as a pulsating testament to that very idea. Thirty-odd years ago, shedding the chains of Soviet-imposed communism, Poland was all systems go, taking the wheel of its own destiny. For the first time, Polish innovation and industry were unleashed, paving the road toward...

Continue Reading
Quantinuum & RIKEN Propel Japan's Quantum Leap Forward

Updated Category News Views 81

Quantum Computing: Japan's Bold New Frontier Quantum computing's buzz is getting louder, and the big players like Quantinuum and RIKEN ain't sitting on their hands. They've rolled up their sleeves to ramp up Japan's quantum-AI supercomputing game with the recent beef-up of Quantinuum's Reimei to its H2 system, putting Japan at the cutting edge of hybrid computing. The...

Continue Reading
AION Labs Elevates Leadership, Eyes New R&D Horizons

Updated Category News Views 70

Setting New Standards in Pharma Innovation The air in Rehovot, Israel might be filled with more than just technological aspirations, thanks to AION Labs stepping up its leadership game. This venture studio doesn't seem content to rest on its laurels. Nope, it's diving headlong into the deeper end of pharma R&D, scouting out fresh tech territories like quantum computing...

Continue Reading
1-800Accountant Secures Global Win in Tax Services

Updated Category News Views 53

Another Feather in the Cap for 1-800Accountant You don’t get to be at the top of your game without turning a few heads. And 1-800Accountant has done just that, snagging the Fall 2026 Clutch Global Award for their expertise in the accounting universe. The Importance of Listening In this day and age, businesses large and small are realizing that the voice of the client is...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Fundraising Campaign to Restore Food Bank Services

Updated Category News Views 160

Transforming Community Support Through Art and Action In the wake of devastating wildfires that impacted a significant area, a new initiative is taking shape to assist those affected. This unique campaign combines the power of art and activism to address an urgent community need: the restoration of a food bank that has served countless families over the past two decades....

Continue Reading
OYO Expands Horizons with Acquisition of G6 Hospitality

Updated Category News Views 67

OYO Acquires G6 Hospitality: A Major Strategic Move In a significant development, Oravel Stays, the parent company of OYO, has announced its acquisition of G6 Hospitality from Blackstone Real Estate for $525 million. This all-cash deal aims to strengthen OYO's presence in the U.S. hospitality industry. Growing Presence in the United States Since diving into the U.S....

Continue Reading
Dizal's Sunvozertinib Receives FDA Priority Review for NSCLC

Updated Category News Views 262

FDA's Priority Review of Sunvozertinib: A Game Changer for NSCLC Dizal is making headlines with the announcement that the U.S. Food and Drug Administration (FDA) has granted priority review for the company's New Drug Application (NDA) for Sunvozertinib. This oral EGFR inhibitor holds the promise of offering a significant treatment option for patients suffering from...

Continue Reading
Deep Dive into Masimo Corporation's Ongoing Legal Troubles

Updated Category News Views 294

Masimo Corporation Under Scrutiny Recently, the spotlight has turned to Masimo Corporation (NASDAQ: MASI) as investigations unfold regarding potential misconduct among its leadership. The inquiry is spearheaded by Charles C. Foti, Jr., a former Attorney General of Louisiana and partner at Kahn Swick & Foti, LLC. Revenue Shortfalls and Investor Concerns The company faced a...

Continue Reading
PMV Pharmaceuticals Unveils Promising Monotherapy Data for Solid Tumors

Updated Category News Views 471

Exciting Developments in Cancer Treatment In the realm of precision oncology, PMV Pharmaceuticals continues to lead the charge with groundbreaking research that shines a spotlight on novel therapies. Today, the company has presented updated interim data that promises to reshape the treatment landscape for patients dealing with advanced solid tumors, particularly those...

Continue Reading